GLP-1 agonists have the potential to become some of the best selling drugs of all time Targeting very large and rapidly growing markets Potential differentiation in dual-acting mechanism, biased signaling, and oral delivery GLP-1/GIP dual agonists have demonstrated greater weight loss than GLP-1 mono-agonists Positive early clinical data Weight loss observed in early clinical trials of CT-388 appears to be lower than that of approved GLP-1 and GLP-1/GIP agonists Will need to demonstrate some level of clinical differentiation, or comparable clinical activity and lower cost, to garner significant revenue Late-stage trials in Type 2 Diabetes and obesity are very expensive Drugs will need to generate billions in annual sales to justify price paid Carmot Therapeutics was acquired by Roche for $2.7 billion in December 2023
You cannot categorise a specific GLP-weight loss plan as the best option
You should seek prompt medical advice if you experience any of the following whilst using any weight loss supplement: Chest pain, palpitations, or shortness of breath Severe headaches or sudden changes in vision Significant mood changes, anxiety, or thoughts of self-harm Signs of allergic reaction , such as rash, swelling, or difficulty breathing Unexplained or rapid weight loss accompanied by other symptoms this requires timely assessment, as it may indicate an underlying medical condition (see NICE NG12 on suspected cancer) Sustainable weight loss is best achieved through gradual, consistent changes rather than rapid interventions
According to research, its generally associated with a lower risk of sexual dysfunction and weight gain compared to many SSRIs
Discard the vial when its expiration or recommended in-use period is reached
Most patients tolerate a two-day delay without significant changes in how the medication works, though some may notice minor fluctuations in hunger levels near the end of that week